Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 22 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Braveheart Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (37): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BRVE, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRVE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 96% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Braveheart Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Braveheart Bio's CFO purchased 27,777 shares for approximately $500,000 on August 7, 2026, boosting total equity by 5% and raising his ownership stake to 0.87%.
Why it matters — An insider's significant share purchase can signal confidence in the company's prospects, making it noteworthy for shareholders and prospective investors monitoring BRVE.
Chairman Chris Viehbacher purchased 83,333 shares valued at approximately $1.5 million as of the August 7, 2026 market close. The transaction increased his direct equity holdings in the company by 16%.
Why it matters — BRVE watchers would note that a director's significant share purchase around the IPO reflects insider confidence in the company.
Braveheart Bio CEO Travis Murdoch exercised options to acquire 83,333 shares at $18.00 per share, a transaction totaling $1.5 million, bringing his direct holdings to 2,940,670 shares.
Why it matters — A significant insider share purchase by the CEO may signal management confidence in the company to BRVE watchers.
As at 22 Aug 2026, Braveheart Bio, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (37 of 100).
No analyst covering Braveheart Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRVE are extrapolating price history, which says nothing about the business.
Braveheart Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases.
The most recent item we track (The Motley Fool, 10 Aug 2026): "Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?". Braveheart Bio's CFO purchased 27,777 shares for approximately $500,000 on August 7, 2026, boosting total equity by 5% and raising his ownership stake to 0.87%.
Braveheart Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its current work centers on oral small-molecule cardiac myosin inhibitors, led by BHB-1893, an investigational treatment being developed for both obstructive and non-obstructive forms of hypertrophic cardiomyopathy. The company’s programs are designed to address the underlying mechanics of heart muscle function, with an emphasis on treatment approaches that may offer a more targeted option for patients with inherited heart conditions. Braveheart Bio operates in the healthcare and biotechnology sectors and is based in San Francisco, California.
CEO Dr. Travis Murdoch B.S., M.D., M.Sc. · 30 employees · United States · https://www.braveheart.bio